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of UVB-Induced Skin Cancer in SKH Mice even with
Co-administration of Cyclosporine A
Brian C. Wulff1, Donna F. Kusewitt2, Anne M. VanBuskirk3, Jennifer M. Thomas-Ahner1, Duncan F. Jason3
and Tatiana M. Oberyszyn1
Transplant immunosuppressants have been implicated in the increased incidence of non-melanoma skin cancer
in transplant recipients, most of whom harbor considerable UVB-induced DNA damage in their skin prior to
transplantation. This study was designed to evaluate the effects of two commonly used immunosuppressive
drugs, cyclosporine A (CsA) and sirolimus (SRL), on the development and progression of UVB-induced non-
melanoma skin cancer. SKH-1 hairless mice were exposed to UVB alone for 15 weeks, and then were treated
with CsA, SRL, or CsAþ SRL for 9 weeks following cessation of UVB treatment. Compared with vehicle, CsA
treatment resulted in enhanced tumor size and progression. In contrast, mice treated with SRL or CsAþ SRL had
decreased tumor multiplicity, size, and progression compared with vehicle-treated mice. CsA, but not SRL or
combined treatment, increased dermal mast cell numbers and TGF-b1 levels in the skin. These findings
demonstrate that specific immunosuppressive agents differentially alter the cutaneous tumor microenviron-
ment, which in turn may contribute to enhanced development of UVB-induced skin cancer in transplant
recipients. Furthermore, these results suggest that CsA alone causes enhanced growth and progression of skin
cancer, whereas co-administration of SRL with CsA causes the opposite effect.
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INTRODUCTION
It is apparent that the immune system as a whole can both
promote and antagonize tumor development (Balkwill and
Mantovani, 2001; de Visser and Coussens, 2005). The
balance between these two roles is influenced by the type
of cancer; the stage of the cancer; the immune cell types
involved; and external influences such as foreign pathogens,
chemical agents, or medications. Inflammation has been
implicated in enhanced carcinogenesis in a number of
organs, including skin (Shacter and Weitzman, 2002; de
Visser and Coussens, 2006; De Marzo et al., 2007). It has
even been stated that the effects of inflammatory cells are as
important to tumor development as alterations in oncogene
and tumor-suppressor genes (Coussens and Werb, 2001).
Many studies have been conducted in vitro using cell lines
and in vivo using chemically induced and orthotopic models
to understand the influences of immune and resident skin
cells on the development and progression of cutaneous
squamous cell carcinoma (SCC). Innate effectors such as
neutrophils and mast cells have been strongly implicated in
carcinogenesis due to their ability to promote inflammation
(Coussens and Werb, 2001). Previously, we showed that
enhanced neutrophil infiltration and activity in the dermis are
highly correlated with increases in UVB-induced tumor
numbers, and that reduction of inflammation using selective
COX-2 inhibitors can reduce the tumor load by 50–70%
(Wilgus et al., 2003). Others have demonstrated that the
presence of tryptase-positive mast cells correlates with poor
prognosis in cancer patients (Takanami et al., 2000; Ribatti
et al., 2003), which is thought to be due to their role in
angiogenesis and tumor metastases (Rojas et al., 2005; Welsh
et al., 2005).
Many cytokines have been shown to be important positive
and or negative mediators of cutaneous inflammation and
& 2008 The Society for Investigative Dermatology www.jidonline.org 2467
ORIGINAL ARTICLE
Received 21 September 2007; revised 28 January 2008; accepted 19 March
2008; published online 8 May 2008
Financial support: NIH grant number 5R01CA109204-03
This work was performed in Columbus, Ohio, USA
1Department of Pathology, The Ohio State University, Columbus, Ohio, USA;
2Department of Carcinogenesis, The University of Texas MD Andersen
Cancer, Center Science Park Research Division, Smithville, Texas, USA and
3Department of Surgery, The Ohio State University, Columbus, Ohio, USA
Correspondence: Dr Tatiana M. Oberyszyn, Department of Pathology,
The Ohio State University, 1645 Neil Avenue, 129 Hamilton Hall,
Columbus, Ohio 43210, USA. E-mail: oberyszyn.1@osu.edu
Abbreviations: CsA, cyclosporine A; IS, immunosuppression;
MISCC, microinvasive squamous cell carcinoma; MOM, Mouse on Mouse;
SCC, squamous cell carcinoma; SRL, sirolimus (aka rapamycin);
TGF-b1, transforming growth factor-b1
skin carcinogenesis depending on the stage of carcinogenesis
that they are present. For example, tumor-necrosis factor-a
promotes cancer initiation but has no effect on progression
(Suganuma et al., 1999), whereas transforming growth factor-
b1 (TGF-b1) exerts potential pro- and anticarcinogenic effects
during cancer initiation, but enhances progression at the later
stages of carcinogenesis (Li et al., 2005). TGF-b1 has also
been shown to cause inflammation when conditionally
expressed in the skin of mice (Liu et al., 2001).
Much work has been done in characterizing the multi-
faceted interactions between immune cells and cancers, but
few studies have addressed the effects of therapeutic
immunosuppression (IS) on the changes in the skin resulting
in increased development of non-melanoma skin cancer.
It is well established that solid-organ transplant recipients
have a dramatically increased incidence of aggressive mali-
gnancies, especially cutaneous malignancies (DiGiovanna,
1998). Furthermore, the majority of organ transplant recipi-
ents (67%) are between the ages of 35–65 (based on Organ
Procurement and Transplant Network data as of 23 March
2007) and therefore most likely have precancerous keratino-
cytes containing UVB-induced damage from years of sun
exposure (Abdulla et al., 2005; Vanbuskirk et al., 2005). In
fact, SCC is the most frequent skin cancer in the transplant
patient population, and the disease in these patients is more
aggressive than in the general population (Buell et al., 2005).
This increase in SCC has been linked to the immunosuppres-
sive agents given to solid-organ transplant recipients to
prevent organ rejection (Otley and Maragh, 2005; Neuburg,
2007). Cyclosporine A (CsA), an older immunosuppressive
drug, is a cyclic-peptide immunosuppressant that inhibits
calcineurin and is reported to have procarcinogenic effects
(Servilla et al., 1987; Tiu et al., 2006). Sirolimus (SRL), a newer
drug, also known as rapamycin, is a macrolide immunosup-
pressant that acts through inhibition of mammalian target of
rapamycin. In addition to its use to prevent organ rejection,
this drug is also currently under investigation as a chemopre-
ventative agent based on reports of its antiangiogenic and
growth-inhibitory effects (Euvrard et al., 2004).
This study was designed to model the clinical situation in
which a patient with a history of sun exposure who, after
receiving a transplant and beginning immunosuppressive
treatment, avoids further sun exposure. Since UVB can
induce and promote carcinogenesis, this study design
removes the confounding effects of UVB-induced promotion
on established tumors in an immunosuppressive milieu.
Therefore, our study brings to light the effects of CsA and SRL
on the development and progression of de novo UVB-
induced cutaneous tumors. We found that CsA-treated mice
had an increase in tumor size and progression associated with
increased cutaneous proinflammatory mediators, which was
not seen with SRL and was blocked when both agents were
given in combination.
RESULTS
Tumor number, size, and total tumor burden
Upon initiation of immunosuppressive treatment, individual
tumors were measured weekly for each mouse. The length
and width of palpable lesions greater than 1mm in any
direction were measured and included in the data set. All
treatment groups had a mean tumor number of less than five
tumors per mouse at the beginning of IS treatment. Tumor
number in the vehicle group steadily increased over the
entire treatment period. There were no differences in tumor
number between SRL and CsAþ SRL treatment groups, but
both were lower than that for vehicle treatment at all time
points (Figure 1a). At early time points of IS, between weeks 2
and 6, CsA-treated mice had more tumors than SRL- and
CsAþ SRL-treated mice. Using linear regression analysis, the
rate of increase for tumor number was significantly decreased
in all three treatment groups compared with the vehicle
(Po0.03; Figure 1a). When tumorsX2mm in diameter were
considered, the vehicle and CsA treatment groups were quite
similar, with a mean of 7.7 and 6.1 tumors per mouse,
whereas both SRL and CsAþ SRL treatment groups were
dramatically lower, with only 1.5 and 1.7 tumors per mouse,
respectively (data not shown). Furthermore, only one in 10
mice had a tumor over 9mm2 in the SRL and CsAþ SRL
treatment groups, whereas CsA and vehicle treatment groups
had means of 2.5 and 2.1 large tumors per mouse,
respectively (data not shown). SRL and CsAþ SRL treatment
groups had significant decreases in average tumor size
compared with vehicle as early as week 5 of IS (Po0.03;
Figure 1b). By 9 weeks of IS, the mean area per tumor for the
CsA treatment group was significantly larger than that for the
vehicle treatment group (Po0.01). The overall effects of the
IS regimes can be seen in Figure 1c, showing total tumor
burden per mouse.
Tumor and lymph node histological grading
In all, 56, 42, 54, and 50 tumors from the vehicle, CsA, SRL,
and CsAþ SRL treatment groups, respectively, were graded
histologically by a board certified veterinary pathologist
(DF Kusewitt). Figure 1d shows the results as the percentage
of tumors in each grade. The majority of tumors in each group
were papillomas. Four microinvasive SCC (MISCCs) (7% of
vehicle tumors graded) were found in the vehicle treatment
group. SRL and CsAþ SRL treatment groups had similar
patterns, with only one SCC (2%) and one MISCC (1.85%),
respectively. Mice treated with CsA developed the most
aggressive tumors, with a total of three SCCs (7%) and four
MISCCs (9%). Figure 2 shows representative pictures of
tumor-bearing mice from each group immediately preceding
killing.
Axillary and inguinal lymph nodes were formalin fixed,
paraffin embedded, and hematoxylin and eosin-stained to be
examined histologically for metastatic SCC. No metastatic
cells were identified in the draining lymph nodes, but it was
observed that the majority of lymph nodes from only the CsA-
treated mice exhibited granulomatous lymphadenitis, char-
acterized by presence of numerous macrophages and
occasional multinucleated giant cells (data not shown).
Identification of dermal infiltrative immune cells
We examined paratumoral dermis for neutrophil and mast
cell presence. Immunohistochemical analysis demonstrated
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that there was a trend toward increased dermal neutrophil
infiltration in CsA-treated mice, but this increase did not
reach significance compared with vehicle-treated mice
(Figures 3b and 4a). A significant increase in the number of
tryptase-positive mast cells was seen in paratumoral dermis of
CsA-treated mice compared with vehicle-, SRL-, and
CsAþ SRL-treated mice (Figures 3c and 4b; Po0.001). Both
SRL and CsAþ SRL treatment groups showed presence of
reduced paratumoral tryptase-positive mast cells, but this
difference was not significant (P¼ 0.3).
Effect of immunosuppressive treatment on cutaneous
cytokine levels
Whole-dorsal skin proTGF-b1 protein levels were assessed by
western immunoblot (Figure 5a) and quantitated (Figure 5b).
ProTGF-b1 level was significantly increased in CsA-treated
dorsal skin compared with that in vehicle-treated skin
(Po0.001). ProTGF-b1 levels decreased slightly in SRL and
CsAþ SRL-treated dorsal skin compared with that in vehicle-
treated skin, although this was not statistically significant
(P¼0.57; Figure 5b).
DISCUSSION
Our study was designed to model the scenario in which
cancer induction and promotion have occurred prior to IS, in
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Figure 1. Tumor progression and grading. Length and width of dorsal neoplastic lesions were measured weekly for 9 weeks following initiation of IS for
calculation of tumor number per mouse (a), mean area per tumor (lengthwidth; b), and total tumor burden per mouse (c). At week 9 of IS, the mean tumor size
for CsA-treated mice was significantly larger than that of vehicle-treated mice (*Po0.01), whereas SRL and CsAþ SRL treatment tumors were significantly
smaller than due to vehicle treatment (*Po0.03). Data points are mean±SEM. Tumors were graded from each treatment group, vehicle (n¼ 56), CsA (n¼ 42),
SRL (n¼ 54), and CsAþ SRL (n¼50), were graded as follows: hyperplasia (striped), papilloma (white), MISCC (speckled), or SCC (black). Percentages of each
grade of tumor are reported in panel (d).
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Figure 2. Skin tumor formation on representative mice from each treatment
group. After week 24 of the study, immediately before mice were killed,
photographs of representative mice from each of the treatment groups were
taken.
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order to begin to understand the changes in the immune
system–skin cancer interactions under the influences of two
prevalent and very different immunosuppressive drugs. Our
findings support data from previous studies demonstrating
that CsA treatment causes an increase in tumor size and
progression (Servilla et al., 1987; Tiu et al., 2006), in
association with increased expression of innate proinflam-
matory immune markers. We have also shown that SRL
treatment reduced tumor number size and progression
compared with vehicle treatment, and these effects were
sufficient to block the changes brought about by CsA when
the two drugs were given simultaneously.
In this study, we have shown that in our model we see this
enhanced growth in terms of increased tumor size, but we
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Figure 3. Tumor-associated immune cell immunodetection. Representative pictures of papilloma histology and histological detection of immune cells
surrounding papillomas. The top row depicts representative pictures of formalin-fixed hematoxylin and eosin-stained papillomas (original magnification  100);
the middle row depicts tryptase-positive mast cells (original magnification  600); and the bottom row depicts paratumoral Ly-6G-positive neutrophils (original
magnification  600). All immunohistochemical assays were developed with diaminobenzidine (brown) and counterstained with hematoxylin (blue).
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Figure 4. Tumor-associated immune cell quantification. Tumor sections
were stained immunohistochemically for neutrophils (a) and tryptase-positive
mast cells (b). The mean number of cells from five fields (original
magnification  600) in the paratumoral dermis were counted. Bars represent
meanþ SEM. CsA treatment resulted in a significant increase in tryptase-
positive mast cells (*Po0.001).
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Figure 5. Dorsal-skin TGF-b1 content. Total protein was isolated from
pulverized mouse dorsal skin and samples were analyzed by immunoblotting
for TGF-b1 content; ‘‘C’’ is the control peptide purchased from Santa Cruz
Biotechnology (a). The exposed film was digitized and ImageJ was used to
determine the integrated density of each band. The mean densityþ SEM
(n¼4) is shown ((b) *Po0.001).
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also see an unexpected reduction in tumor number. This may
be explained by the cessation of UVB irradiation 9 weeks
prior to killing. Recently, Duncan et al. (2007) showed in a
similar model that, with concurrent immunosuppression and
UVB exposure, CsA treatment resulted in a larger number of
tumors. We have not yet been able to clearly dissect out
whether the changes in tumor size resulted from the action of
CsA on the tumor cells themselves or indirectly via alterations
in the immune system or both. However, in this study, the
observed increase in tumor growth caused by CsA was also
associated with mast cell infiltration and TGF-b production.
These changes demonstrate alterations in the immune
response that have been highly associated with increased
tumor progression and poor patient prognosis (Robson et al.,
1996; Ribatti et al., 2003; Leivonen and Kahari, 2007). Mast
cells are a source of tumor-promoting paracrine factors and
have been shown to play a role in tumor metastases (Rojas
et al., 2005). Tryptase itself has been shown to cleave
extracellular substrates, as well as act as an epithelial growth
factor (Payne and Kam, 2004). This suggests that had we been
able to continue treatment beyond 25 weeks, we may have
seen an increase in metastatic lesions in the CsA-treated
group. The lack of metastases is not surprising, since even
with continued UV exposure we do not see metastases in
immunocompetent mice in this mouse model until after 30
weeks.
While the precise mechanisms by which it works are not
yet clear, TGF-b has been implicated in epithelial tumor
progression. A recent study by Byrne et al. (2008) demon-
strated that transfecting a murine regressing skin tumor with
TGF-b enabled the tumors to grow progressively. TGF-b1 has
been shown to promote inflammation (Liu et al., 2001) in the
skin as well as epithelial-to-mesenchymal transition (Han
et al., 2005), important components of the tumorigenesis
process. We are not the first to find a link between CsA
treatment, increased levels of TGF-b and tumor growth. Hojo
et al. reported that CsA treatment enhanced adenocarcinoma
growth in immunodeficient severe combined immunodefi-
cient-beige mice and that anti-TGF-b antibodies prevented
CsA-induced increases in metastases (Hojo et al., 1999). They
concluded that CsA-induced TGF-b production was involved
in the ability of CsA to promote cancer progression. In this
study, we detected increased TGF-b1 levels in the skin of
mice with tumors of higher grade; however, we were not able
to isolate the source of the TGF-b1, which can be produced
by many cell types, including mast cells and keratinocytes.
Further studies will be designed to identify the source of this
cytokine in our model.
The ability of SRL to block the pro-tumor effects of CsA in
this model when given in combination, are not surprising
considering SRL has been shown to reduce growth of non-
melanoma skin cancer (Brown et al., 2006; Khariwala et al.,
2006). Other groups have also shown an ability of SRL to
reduce tumor growth in the presence of CsA (Silva et al.,
2004).
In conclusion, we have shown important differences in the
microenvironment of tumors isolated from the various IS
treatment groups. These data support the theory that specific
immunosuppressants differentially contribute to the skin
carcinogenesis process and suggest that combined CsA and
SRL suppressive therapy for solid-organ transplant recipients
may be beneficial with regards to non-melanoma skin cancer
development. More surprisingly, our findings suggest that,
even without continued UVB exposure, treatment with CsA
can cause changes in the skin that lead to increased growth
and progression of UVB-induced skin cancer, and suggest
that the skin of patients on CsA may need to be even more
closely monitored than previously believed.
MATERIALS AND METHODS
Animals and experimental design
Female SKH-1 hairless mice (6–8 weeks, 26–30 g) were purchased
from Charles River Laboratories (Wilmington, MA) and housed in a
facility approved by the American Association for the Accreditation
of Laboratory Animal Care. Water (containing Baytril) and food were
given ad libitum. Animals were irradiated thrice weekly on non-
consecutive days for 15 weeks. Phillips FS40 UVB bulbs (American
Ultraviolet Company, Murray Hill, NJ) with Kodacel filters (Eastman
Kodak, Rochester, NY) were used to deliver 2240 Jm2 UVB per
exposure as determined by a UVR meter equipped with a UVB
sensor (UVP Inc., Upland, CA). The UVB output was monitored
biweekly to ensure consistent exposure throughout the experiment.
This dose of UVB has been determined to be one minimal erythemic
dose in our laboratory. After 15 weeks, UVB treatments were
terminated and mice were assigned to one of four treatment groups:
CsA alone (20mg kg1, n¼ 8), SRL alone (2mg kg1, n¼ 10),
CsAþ SRL (10 and 2mg kg1, respectively, n¼ 10), or vehicle
control (n¼ 10), so that each group contained the same total number
of tumors. IS or vehicle treatment was administered intraperitoneally
daily for 9 weeks. An injectable form of CsA, Sandimmune (Novartis,
Basel, Switzerland), and SRL (Rapamycin; LC Laboratories Inc.,
Woburn, MA) were used. The vehicle control was composed of
350mgml1 cremophor EL, 37.5% ethyl alcohol, and 0.2% DMSO,
in phosphate-buffered saline. The area (lengthwidth) of individual
tumors on each mouse was measured weekly to quantify tumor
number, size, and total tumor area. Only tumors X1mm in any
direction were included in the data set. At the end of 24 weeks and
24 hours after the final immunosuppressive treatment, mice were
killed by lethal inhalation of carbon dioxide.
Sample preparation
Immediately after mice were killed, tumors were excised individu-
ally. Six tumors (two small, two medium, and two large) per mouse
were selected based on the size range within each treatment group.
Tumors were excised with surrounding uninvolved skin, and either
frozen in OCT or fixed for 2 hours in 10% neutral buffered formalin
and paraffin-embedded. After removal of all remaining tumors,
‘‘tumor-free’’ dorsal skin was flash frozen in liquid nitrogen for
analysis of cytokine content. Axillary and inguinal lymph nodes
were formalin fixed overnight and paraffin-embedded.
Tumor and lymph node grading
Sections of paraffin-embedded tumors (5-mm thick) and frozen
tumors were cut and stained with hematoxylin and eosin. Tumor
sections were graded in a blinded manner by a board certified
veterinary pathologist (DF Kusewitt). Grades were assigned as
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follows: hyperplasia, papilloma, MISCC, or fully invasive SCC.
Papillomas were exophytic tumors showing no evidence of stromal
invasion and ranged from epithelium without a pronounced
papillary pattern to having a well-differentiated papillary mass with
a few finger-like projections of atypical cells at the base of the mass.
MISCCs were categorized by penetration into the dermis. Only
tumors that invaded all the way to the panniculus carnosus and had
a more endophytic appearance, with stromal invasion evidenced by
loss of basement membrane continuity and development of an
inflammatory stromal response, were classified as fully invasive
SCCs. Hyperplasias and papillomas were considered benign,
whereas SCCs and MISCCs were considered malignant. Axillary
and inguinal lymph nodes were formalin-fixed and paraffin-
embedded. Sections of axillary and inguinal lymph nodes (5-mm
thick) were hematoxylin and eosin-stained and examined histologi-
cally for metastatic SCCs.
Antibodies
Rat anti-mouse Ly-6G was purchased from BD Pharmingen (San
Diego, CA). Mouse anti-human mast cell tryptase was purchased
from Chemicon (Temecula, CA). Rabbit anti-mouse TGF-b1 was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit
anti-rat and goat anti-rabbit biotinylated secondary antibodies were
purchased from Pierce (Rockford, IL).
Immunohistochemistry
Tryptase-positive mast cells were detected using the Mouse on
Mouse (MOM) detection kit (Vector Laboratories, Burlingame, CA).
Sections (5-mm thick) were cut from formalin-fixed, paraffin-
embedded papillomas from each mouse. Sections were rehydrated
by washing in Clearite, and then in a series of graded ethanol washes
ending in water. Endogenous peroxidase activity was blocked with
3% H2O2 in methanol for 10minutes, followed by a 1-hour
incubation in MOM blocking buffer. Sections were incubated with
mouse anti-tryptase antibody, in MOM diluent for 1 hour at room
temperature, and then treated for 30minutes with MOM biotinylated
anti-mouse secondary antibody in MOM diluent. A 15-minute
incubation with Vectastain elite ABC reagent (Vector Laboratories)
was followed by development with diaminobenzidine. Samples
were counterstained with Meyer’s hematoxylin, dehydrated through
a graded series of ethanol washes with a final wash in Clearite, and
mounted with Vectamount (Vector Laboratories). Detection of
Ly-6Gþ Cells, as a marker for neutrophils, was performed as described
previously by Wilgus et al. (2003). The mean number of cells per field
was determined by counting five fields (original magnification  600)
within the papillomas or in the paratumoral dermis.
TGF-b1 content
ProTGF-b1 was detected by western immunoblot analysis. Briefly,
50mg of total protein from whole-back skin was electrophoresed
under reducing conditions with Laemmli buffer (BioRad, Hercules,
CA) in a 12.5% criterion polyacrylamide gel (BioRad). The protein
was transferred, via electrophoresis, to polyvinylidene difluoride
membrane. Nonspecific binding was blocked with 5% BSA in Tris-
buffered saline with 0.1% Tween-20 and incubated with anti TGF-b1
antibody over night at 41C. After rinsing in Tris-buffered saline with
0.1% Tween-20, the membrane was incubated with Pierce horse-
radish peroxidase-conjugated goat anti-rabbit antibody for 1 hour. The
immunocomplex was detected with super signal pico chemilumines-
cent substrate (Pierce) and was exposed to BioMax film (Kodak).
Statistics
Linear regression modeling was used to compare the shift and slope
of the tumor number and total average tumor area over time. Data
for these tests was transformed with square root and natural
logarithm, respectively, and fitted to a model with the equation.
Y¼ b0þb1Wþ b2ICsAþ b3ISRLþ b4ICsAþ SRLb5WICsAþ b6WISRLþ
b7WICsAþ SRL, where W¼weeks of treatment and I¼ binomial
indicator variable (that is, Icsa¼ 1 if CsA was used and 0 if CsA
was not used). General linear modeling with Dunnett’s method
and a¼ 0.05 was used for all other comparisons. Po0.05 was
considered statistically significant. Statistical analysis was
performed using the SPSS version 16.
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